Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for potential conditions affecting brain health.
Oragenics Issues Update to Shareholders
Oragenics, Inc. (NYSE American: OGEN):
